ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
3
views
0
references
Top references
cited by
3
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
4,775
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
Ivermectin as an inhibitor of cancer stemlike cells
Author(s):
G Dominguez-Gomez
,
A Chávez-Blanco
,
JL Medina-Franco
,
F. Saldívar-González
,
Y. Flores-Torrontegui
,
M. Juárez
Publication date:
2018
Journal:
Mol Med Rep
Read this article at
ScienceOpen
Bookmark
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Gamma Delta T cells
Data availability:
Comments
Comment on this article
Sign in to comment
Similar content
4,775
TP53 Mutation, Epithelial-Mesenchymal Transition, and Stemlike Features in Breast Cancer Subtypes
Authors:
Danila Coradini
,
Marco Fornili
,
Federico Ambrogi
…
Mesenchymal stemlike cells in glioblastoma.
Authors:
Anh Nhat Tran
,
Craig Horbinski
Expression profile of cancer-related genes in human adult bone marrow-derived neural stemlike cells highlights the need for tumorigenicity study.
Authors:
R Zhu
,
Xiaodan Jiang
,
Mouxuan Du
…
See all similar
Cited by
3
Combinations of ivermectin with proteasome inhibitors induce synergistic lethality in multiple myeloma
Authors:
Hongmei Luo
,
Yu Feng
,
Fangfang Wang
…
Ivermectin ameliorate the toxic effect of dimethylhydrazine in male Wistar rats
Authors:
Mohammed Al-zharani
,
Hamzah A. Alghamdi
,
Badr A. Aldahmash
…
Fármacos de reposicionamiento y fármacos específicos en fase preclínica para la COVID-19
Authors:
Carlos Cabrera-Sánchez
,
J. Sánchez-Godínez
,
Yolanda Gonzalez
See all cited by